The bacterium Clostridioides difficile is named “difficult” for a reason. Originally it was hard to grow in the lab, and now ...

diff in check. A gold standard C. diff treatment, the antibiotic vancomycin, brought her a little relief but quickly set the stage for more trouble. It further wiped out protective gut bacteria, ...

Updated guidelines recommend fidaxomicin as the first-line agent for C difficile infection, but researchers found use in US ...

C. difficile spores are highly resistant to desiccation, chemicals and extreme temperature. Spores frequently contaminate the environment around patients with CDI, potentially persisting for ...

Discover Merck's groundbreaking patent on genetic markers linked to enhanced C. difficile treatment responses. Learn how personalized therapy can improve patient outcomes.

Study finds underutilization of fidaxomicin, a recommended treatment for C. diff infection, despite increased use in hospitals.

In fact, C. diff infections often spring up because the bacteria take advantage of a weakened microbiome following treatment with antibiotics for other diseases. “Treatment of C. difficile ...

The ongoing trial is testing the therapy – RBX2660 – as a treatment for Clostridioides difficile infection or C. diff, a bacterium that causes diarrhoea and inflammation in the colon and is a ...

The product is based on purified Firmicutes bacterial spores delivered in an oral capsule that is designed to encourage the regrowth of healthy bacteria after antibiotic treatment for C.